Clinical Trial Update: A Randomized Phase II Trial of Surgery Plus Sorafenib vs. Sorafenib Alone for Hepatocellular Cancer (HCC) With Portal Vein Invasion [Phase 2]

View source ↗

Summary

A randomized Phase II trial evaluating surgery plus sorafenib versus sorafenib alone for hepatocellular carcinoma with portal vein invasion.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Hepatocellular Cancer

Drugs mentioned

• Sorafenib (Sorafenib)

Snippet

Sponsor: White Plains Hospital | Conditions: Hepatocellular Cancer | Phase 2 | Status: UNKNOWN